U.S. stock futures rose on Thursday following Wednesday's advances as investors digest tariff pauses amid earnings reports.

Coherent reported quarterly earnings of 95 cents per share which beat the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $1.44 billion which beat the analyst ...

SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- LiveRamp ® (NYSE: RAMP), the leading data collaboration platform, today announced its financial results for the fiscal 2025 third quarter ended ...

1 Day RANI 5.67% DJIA 0.30% Russell 2K -0.61% Health Care/Life Sciences -1.75% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

You can get a prescription online or in person. Ozempic (semaglutide) is an injectable medication initially designed to manage type 2 diabetes. Over the past few years, its potential to aid weight ...

which has investors very interested in Viking Therapeutics‘ (NASDAQ:VKTX) VK2735, which is showing better efficacy than Novo Nordisk’s semaglutide in clinical trials. Renaissance Technologies ...

Novo Nordisk reported that adults with obesity achieved significant weight loss using their semaglutide treatment, but their shares dipped following the announcement. In contrast, Viking Therapeutics' ...